Jefferies upgraded Chemed (CHE) to Buy from Hold with a price target of $550, up from $490. The company’s fiscal 2026 reimbursement, particularly in Florida, came in more favorable than expected, the analyst tells investors in a research note. The firm believes this positions Chemed for 2026 EBITDA at the high end of the current Street range. Better than expected reimbursement and “aggressive” share buybacks should drive the stock’s multiple higher in the near-term, contends Jefferies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
- Optimistic Outlook for Chemed: Buy Rating Supported by Favorable Medicare Rates and Strategic Share Repurchases
- Chemed board authorizes additional $300M for stock repurchases
- Chemed board declares increased quarterly dividend of 60c per share
- Chemed price target lowered to $580 from $650 at Oppenheimer
- Chemed’s Earnings Call: Challenges and Growth